Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
atezolizumab + sacituzumab govitecan
- Development stage
- Unknown
- Lead developer
- Gilead Sciences
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
A combination therapy consisting of atezolizumab (Tecentriq), a PD-L1 inhibitor, and sacituzumab govitecan (Trodelvy), a Trop-2-directed antibody-drug conjugate. This combination is being investigated primarily for triple-negative breast cancer (TNBC). Atezolizumab works by blocking the PD-L1 pathway, enhancing immune system recognition of cancer cells, while sacituzumab govitecan delivers the topoisomerase inhibitor SN-38 directly to Trop-2-expressing cancer cells, causing DNA damage and cell death.
- Brand names
- TrodelvyTecentriq
- Other names
- sacituzumab govitecan-Dana-Farber Cancer Institute-triple-negative breast cancerASPRIA regimenatezolizumab and sacituzumab govitecan
02
Targets
TOP1 (DNA Topoisomerase I)TACSTD2 (Tumor-associated calcium signal transducer 2)CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on atezolizumab + sacituzumab govitecan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on atezolizumab + sacituzumab govitecan.